Drugs / IL12-L19L19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04471987 | Jul 2020 → Dec 2026 expected | metastatic malignant neoplasm | Philogen S.p.A. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL12-L19L19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04471987 ↗ |
| Modality | Monoclonal antibody | “Human Monoclonal Antibody-cytokine Fusion Protein” NCT04471987 ↗ |